Anne Blaes1,2, Heather Beckwith3,4, Natalia Florea5, Robert Hebbel3, Anna Solovey3, David Potter3,4, Douglas Yee3,4, Rachel Vogel6,4, Russell Luepker5, Daniel Duprez5. 1. Division of Hematology/Oncology, University of Minnesota, 420 Delaware Street, S.E., MMC 480, Minneapolis, MN, 55455, USA. Blaes004@umn.edu. 2. Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA. Blaes004@umn.edu. 3. Division of Hematology/Oncology, University of Minnesota, 420 Delaware Street, S.E., MMC 480, Minneapolis, MN, 55455, USA. 4. Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA. 5. Division of Cardiology, University of Minnesota, Minneapolis, MN, USA. 6. Division of Gynecology/Oncology, University of Minnesota, Minneapolis, USA.
Abstract
PURPOSE: Aromatase inhibitors (AI) have been shown to reduce breast cancer-related mortality in women with estrogen positive (ER+) breast cancer. The use of AIs, however, has been associated with higher rates of hypertension, hyperlipidemia, and cardiovascular (CV) events. METHODS: A cross-sectional study of 25 healthy postmenopausal women and 36 women with curative intent breast cancer on an AI was performed to assess endothelial dysfunction, an indicator of risk for CV events. Consented subjects underwent vascular testing using the HDI/Pulse Wave CR-2000 Cardiovascular Profiling System and the EndoPAT2000 system. RESULTS: Mean age was 61.7 and 59.6 years (cases, controls). Most subjects were Caucasian and overweight. Controls had a lower mean systolic blood pressure (128.6 mmHg vs. 116.2 mmHg, p = 0.004). Median estradiol levels were reduced in cases (2 vs. 15 pg/ml, p < 0.0001). EndoPAT ratio (0.8 vs. 2.7, p < 0.0001) was significantly reduced in cases as compared to controls. Median large artery elasticity (12.9 vs. 14.6 ml/mmHg × 10, p = 0.12) and small artery elasticity (5.2 vs. 7.0 ml/mmHg × 100, p = 0.07) were also reduced though not statistically significant. There was no correlation between use of chemotherapy, radiation therapy, type of AI, or duration of AI use and endothelial function. When adjusting for differences in blood pressure, results remained significant. CONCLUSION: Breast cancer cases on AIs have reductions in endothelial function, a predictor of adverse CV disease. IMPACT: Vascular function changes in breast cancer cases on AIs compared to postmenopausal women. Further work is needed to evaluate vascular changes over time.
PURPOSE: Aromatase inhibitors (AI) have been shown to reduce breast cancer-related mortality in women with estrogen positive (ER+) breast cancer. The use of AIs, however, has been associated with higher rates of hypertension, hyperlipidemia, and cardiovascular (CV) events. METHODS: A cross-sectional study of 25 healthy postmenopausal women and 36 women with curative intent breast cancer on an AI was performed to assess endothelial dysfunction, an indicator of risk for CV events. Consented subjects underwent vascular testing using the HDI/Pulse Wave CR-2000 Cardiovascular Profiling System and the EndoPAT2000 system. RESULTS: Mean age was 61.7 and 59.6 years (cases, controls). Most subjects were Caucasian and overweight. Controls had a lower mean systolic blood pressure (128.6 mmHg vs. 116.2 mmHg, p = 0.004). Median estradiol levels were reduced in cases (2 vs. 15 pg/ml, p < 0.0001). EndoPAT ratio (0.8 vs. 2.7, p < 0.0001) was significantly reduced in cases as compared to controls. Median large artery elasticity (12.9 vs. 14.6 ml/mmHg × 10, p = 0.12) and small artery elasticity (5.2 vs. 7.0 ml/mmHg × 100, p = 0.07) were also reduced though not statistically significant. There was no correlation between use of chemotherapy, radiation therapy, type of AI, or duration of AI use and endothelial function. When adjusting for differences in blood pressure, results remained significant. CONCLUSION:Breast cancer cases on AIs have reductions in endothelial function, a predictor of adverse CV disease. IMPACT: Vascular function changes in breast cancer cases on AIs compared to postmenopausal women. Further work is needed to evaluate vascular changes over time.
Entities:
Keywords:
Aromatase inhibitors; Breast cancer; Cardiotoxicity; Endothelial function; Vascular function
Authors: Judy N Jacobse; Lars C Steggink; Michael Schaapveld; Gabe S Sonke; Annemiek van Ommen-Nijhof; Joop D Lefrandt; Jourik A Gietema; Flora E van Leeuwen Journal: Breast Cancer Res Treat Date: 2022-10-01 Impact factor: 4.624
Authors: Avirup Guha; Yan Gong; David DeRemer; Jocelyn Owusu-Guha; Susan F Dent; Richard K Cheng; Neal L Weintraub; Neeraj Agarwal; Michael G Fradley Journal: J Cardiovasc Pharmacol Date: 2022-10-01 Impact factor: 3.271
Authors: Anne H Blaes; Daniel A Mulrooney; Rachel Isaksson Vogel; Anna Solovey; Robert Hebbel; Bruce A Peterson; Joseph P Neglia; Carter Biewen; Suma H Konety; Daniel A Duprez Journal: Vasc Health Risk Manag Date: 2018-09-10
Authors: Leah L Zullig; Anthony D Sung; Michel G Khouri; Shelley Jazowski; Nishant P Shah; Andrea Sitlinger; Dan V Blalock; Colette Whitney; Robin Kikuchi; Hayden B Bosworth; Matthew J Crowley; Karen M Goldstein; Igor Klem; Kevin C Oeffinger; Susan Dent Journal: JACC CardioOncol Date: 2022-06-21
Authors: Lisa Prior; Hannah Featherstone; David O'Reilly; Killian Nugent; Marvin Lim; John McCaffrey; Michaela J Higgins; Catherine M Kelly Journal: Cardiooncology Date: 2021-02-23